ReviewBritish journal of pharmacology2019
β
Review in British journal of pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 50 citations in OpenAlex.
- Navigating the challenges of overactive bladder management in women.World journal of urology · 2026Review
- Efficacy and Safety of Mirabegron in Frail Older Adults with Overactive Bladder.Drugs & aging · 2026Review
- Article
- Target and off-target effects of vibegron on smooth muscle contraction of human detrusor and prostate tissues.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Novel insights into β3-adrenoceptor function in a model of retinopathy of prematurity: the contribution of astrocytes to retinal protection.Frontiers in neuroscience · 2026Article
- Immunohistochemical study of Rho-kinase pathway expression in a mouse model of prostate hypertrophy for preliminary study of progressive prostate cancer model establishment.Translational andrology and urology · 2025Article
- Therapeutic Potential of the β3-Adrenergic Receptor and Its Ligands in Cardiovascular Diseases.International journal of molecular sciences · 2025Review
- Mirabegron exhibits antibacterial and Immunomodulatory activities demonstrated by in vitro and in vivo studies.Scientific reports · 2025Article
- βNeurourology and urodynamics · 2025Review
- Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes.World journal of urology · 2025Review
- Association analysis of ADRB3:rs4994 with urodynamic outcome, six months after a single intra-detrusor injection of botulinum toxin, in women with overactive bladder.Pharmacological reports : PR · 2024Article
- The Role of 5-Phosphodiesterase Inhibitors (PDE-5I) in Current Benign Prostatic Hyperplasia Treatment: A Narrative Review.Medicina (Kaunas, Lithuania) · 2024Review
- Article
- Ligand-Receptor Interactions and Structure-Function Relationships in Off-Target Binding of the βInternational journal of molecular sciences · 2024Article
- Pathophysiology of Overactive Bladder and Pharmacologic Treatments Including β3-Adrenoceptor Agonists -Basic Research Perspectives.International neurourology journal · 2024Article
- Presynaptic Adrenoceptors.Handbook of experimental pharmacology · 2024Review
- Dynamic phenotypic shifts and M2 receptor downregulation in bladder smooth muscle cells induced by mirabegron.Frontiers in pharmacology · 2024Article
- Adrenoceptors in the Lower Urinary Tract.Handbook of experimental pharmacology · 2024Review
- Molecular Mechanisms of Neurogenic Lower Urinary Tract Dysfunction after Spinal Cord Injury.International journal of molecular sciences · 2023Review
- Inhibition of prejunctional parasympathetic pathways by βFrontiers in pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
β
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.